Abstract: Some embodiments relate to a method for performing a battery power-based control of an in-call experience based on shared battery power information. Some embodiments relate to a coating of a headset that has a first emissivity over an ultraviolet band and a near-infrared band, a second emissivity over a visible band, and a third emissivity over a mid-to-far infrared band. Some embodiments relate to an aggregate coating of a headset. A thin films is applied to a surface of the headset, and a paint coating is applied to a surface of the thin film to form the aggregate coating. Some embodiments relate to a method for a high-definition multimedia interface derived network timing for distributed audio-video synchronization. Some embodiments relate to a battery containment structure with a metal chassis having surfaces coated with electrical insulators configured to receive a battery, and a lid coupled to the metal chassis.

Abstract: A method and apparatus for shaping fuselage sections. A first fuselage section is held in a holding structure in a cradle in a cradle system. Force are applied to the first fuselage section with an actuator system to a portion of the first fuselage section such that a first current shape of the first fuselage section changes towards a first desired shape for the first fuselage section to join the first the fuselage section to a second fuselage section.

Abstract: A method and apparatus for shaping fuselage sections. A first fuselage section is held in a holding structure in a cradle in a cradle system. Force are applied to the first fuselage section with an actuator system to a portion of the first fuselage section such that a first current shape of the first fuselage section changes towards a first desired shape for the first fuselage section to join the first the fuselage section to a second fuselage section.

Abstract: A web application may be used to take an on-line application for an annuity. The application may collect the applicant's personal information (e.g., name, address, etc.), type of annuity applied for (e.g., immediate or deferred, retirement or non-retirement, etc.), sources of funding, beneficiaries, etc. The web application may also allow the application to be signed electronically. The web application may take application for annuities that are supported by various different types of back-end systems, and may provide the information collected from the applicant to the appropriate back-end system.

Abstract: The invention relates to an in vitro cell based expression system for overexpressing heterologous pump proteins associated with drug resistance into the membrane of the host cell for drug screening applications.

Abstract: Systems and methods for processing defaulted loans are described. In some embodiments, the systems and methods process a defaulted loan by associating the defaulted loan with a loan state, identifying a loan event that relates the loan state to another loan state, and, based on detecting the identified loan event, performing a loan task associated with the identified loan event.

Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Abstract: Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, and opioids. The compounds are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.

Abstract: Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2- dimethylpentanamides which are useful in preventing the intestinal absorption of cholesterol and also increasing high-density lipoprotein (HDL) cholesterol, as well as novel pharmaceutical compositions and methods of use, as well as processes for their manufacture are herein described.

Abstract: Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2-dimethylpen tan amides which are useful in preventing the intestinal absorption of cholesterol and also increasing high-density lipoprotein (HDL) cholesterol, as well as novel pharmaceutical compositions and methods of use, as well as processes for their manufacture are herein described.

Abstract: Certain trisubstituted anilides of oleic, linoleic, and linolenic acid are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Abstract: Certain substituted amides of saturated fatty acids are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Abstract: Certain disubstituted pyrimidineamides of oleic and linoleic acids are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Abstract: Certain substituted amides of saturated fatty acids are potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol.

Abstract: Novel substituted benzimidazol-2-yl-phenoxyalkanoic acids, salts and esters thereof and 3H-imidazo[4,5-b]pyridin-2-yl phenoxy-alkanoic acid, salts, and esters which are useful as antiarteriosclerotic agents are disclosed. The compounds elevate the high density lipoprotein fraction of cholesterol and also lower the low density lipoprotein fraction of cholesterol. Methods for preparing and using the compounds are included.

Abstract: New substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides which are useful as anti-arteriosclerotic agents are disclosed. These compounds elevate the high density lipoprotein fraction of cholesterol, and also lower the low density lipoprotein fraction of cholesterol.

Abstract: New substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides which are useful as anti-arteriosclerotic agents are disclosed. These compounds elevate the high density lipoprotein fraction of cholesterol, and also lower the low density lipoprotein fraction of cholesterol.